Hematology-Oncology
Ahn, Myung Ju
95 AppointmentProfessor, Department of Hematology & Oncology, Samsung Medical Center
Speciality Interests
Schedule
04 | MON 22 |
TUE 23 |
WEN 24 |
THU 25 |
FRI 26 |
---|---|---|---|---|---|
AM | available | available | |||
PM | available |
Medical School
2010~2012 Ph.D. in Medicine Graduate School, Hanyang University, Seoul, KOREA 2004~2007 Master of Science Graduate School, Hanyang University, Seoul, KOREA 1981~1985 M.D. College of Medicine, Hanyang University, Seoul, KOREA 1979~1981 Premedicine College of Natural Science, Hanyang University, Seoul, KOREA
Specialty Training
Fellowship | 1993~1995 Postdoctoral Fellowship Memorial Sloan-Kettering Cancer Center, New York, U.S.A 1991~1993 Hematology-Oncology, Asan Medical Center Univesity of Ulsan, Seoul, KOREA |
|
---|---|---|
Residency | 1986~1989 Internal Medicine, Hanyang University Hospital, Seoul, KOREA | |
Internship | 1985~1986 Medicine, Hanyang University Hospital, Seoul, KOREA |
Other Education
2006~Present Professor Division of Hematology-oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
2005~2006 Professor "Division of Hematology-Oncology, Department of Medicine, Hanyang University Hospital, Seoul, KOREA
2000~2004 Associate Professor Division of Hematology-Oncology, Department of Medicine, Hanyang University Hospital, Seoul, KOREA
1995~1999 Assistant Professor Division of Hematology-Oncology, Department of Medicine, Hanyang University KURI Hospital, Kyunggi-do, KOREA
Participation in Academic Societies
and Research
Present Member Korean Medical Association
Present Member Korean Association of Internal Medicine
Present Member Korean Association of Cancer
Present Member Korean Society of Medical Oncology
Present Member Korean Association for Lung Cancer
Present Member American Association for Cancer Research
Present Member American Society of Clinical Oncology
Present Member International Association for the Study of Lung Cancer
Present Member European Society of Medical Oncology
Present Member Korean Cancer Study Group
Thesis
ESMO OPEN 2021 10.1016/j.esmoop.2021.100113
Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours
PROCESSES 2021 10.3390/pr9050792
Comprehensive Analysis of Mutation-Based and Expressed Genes-Based Pathways in Head and Neck Squamous Cell Carcinoma
J THORAC ONCOL 2021 10.1016/j.jtho.2020.12.002
Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations
J CLIN ONCOL 2021 10.1200/JCO.20.03025
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer
CANCER 2021 10.1002/cncr.33571
High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean lung liquid versus invasive biopsy program